Craneware (CRW) Share Price, News & Analysis

Company Overview

The Craneware Group, the market leader in automated value cycle solutions, including 340B management, collaborates with U.S. healthcare providers to plan, execute, and monitor operational and financial performance so they can continue to deliver quality care to their communities. Customers choose The Craneware Group's Trisus data and applications platform as their key to navigating the journey to financially sustainable value-based care. Trisus combines revenue integrity, cost management, 340B performance, and decision enablement into a single, SaaS-based platform. Trisus Chargemaster secured top ranking in the Chargemaster Management category of the "2023 Best in KLAS Awards: Software & Services" and is part of an extensive value cycle management suite. The Craneware Group - transforming the business of healthcare.

Key Stats

• Today's Range: 1,800 to 1,840
• 50-Day Range: 1,510 to 1,905
• 52-Week Range: 1,330 to 2,509.20
• Volume: 47,502 shs
• Average Volume: 87,684 shs
• Market Capitalization: £777.69 million
• P/E Ratio: 66.87
• Dividend Yield: 1.60%
• Price Target: GBX 2,800
• Consensus Rating: Buy

Craneware Stock Analysis - MarketRank™

Craneware scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Craneware has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Craneware has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Craneware is 66.87, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Craneware is 66.87, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.87.

Price to Book Value per Share Ratio

Craneware has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CRW.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Craneware pays a meaningful dividend of 1.44%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Craneware does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Craneware is 107.14%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for CRW.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Craneware has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Craneware this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for CRW on MarketBeat in the last 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Craneware insiders have bought more of their company's stock than they have sold. Specifically, they have bought £30,270.24 in company stock and sold GBX 0 in company stock.

Percentage Held by Insiders

19.28% of the stock of Craneware is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

60.17% of the stock of Craneware is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CRW Stock Analysis - Frequently Asked Questions

How have CRW shares performed this year?

Craneware's stock was trading at GBX 2,110 at the start of the year. Since then, CRW shares have decreased by 14.2% and is now trading at GBX 1,810.
View the best growth stocks for 2025 here.

How do I buy shares of Craneware?

Shares of CRW stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Craneware own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Craneware investors own include Rolls-Royce Holdings plc (RR.L), accesso Technology Group (ACSO), Greencore Group (GNC), Nikola (NKLA), ASOS (ASC), Babcock International Group (BAB) and ChargePoint (CHPT).

Company Calendar

• Record date for 4/17 Dividend: 3/20/2025
• Ex-Dividend for 4/17 Dividend: 3/20/2025
• Dividend Payable: 4/17/2025
• Today: 5/07/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Health Information Services
• Sub-Industry: N/A
• Current Symbol: LON:CRW
• CIK: N/A
• Web: public.craneware.com
• Phone: +44-131-5503100
• Fax: N/A
• Employees: 734
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 2,800
• High Stock Price Target: GBX 2,800
• Low Stock Price Target: GBX 2,800
• Potential Upside/Downside: +54.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 27.07
• Trailing P/E Ratio: 66.87
• Forward P/E Ratio: 23.03
• P/E Growth: N/A
• Net Income: £14.27 million
• Net Margins: 6.18%
• Pretax Margin: N/A
• Return on Equity: 3.58%
• Return on Assets: 2.28%

Debt

• Debt-to-Equity Ratio: 12.22
• Current Ratio: 0.63
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: £230.77 million
• Price / Sales: 3.37
• Cash Flow: GBX 122.99 per share
• Price / Cash Flow: 14.72
• Book Value: GBX 932.46 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 42,966,569
• Free Float: N/A
• Market Cap: £777.69 million
• Optionable: Not Optionable
• Beta: 0.28